LifeMD has introduced a limited-time $299 introductory bundle for new self-pay patients prescribed Wegovy, combining the medication with comprehensive virtual weight management services. The offering represents a significant collaboration between the virtual primary care provider and pharmaceutical giant Novo Nordisk, designed to improve access to FDA-approved GLP-1 therapy for patients seeking alternatives to compounded medications.

The bundle structure provides Wegovy at a discounted price of $199 for eligible patients, with an additional $100 covering LifeMD's clinical care, onboarding, and ongoing support services. This pricing is available through LifeMD's recently completed integration with NovoCare Pharmacy, enabling streamlined prescription fulfillment within the company's vertically integrated platform.

Following the introductory month, the program continues at $599 per month with no long-term commitment required. The promotional pricing applies to eligible patients prescribed Wegovy on or before June 30, 2025, creating urgency for patients considering the transition from compounded alternatives to FDA-approved therapy.

"Our collaboration with Novo Nordisk reflects LifeMD's commitment to improving affordability, convenience, and access for patients seeking medically guided weight loss," said Justin Schreiber, Chairman and CEO of LifeMD. "This bundled solution provides a seamless, affordable on-ramp to FDA-approved GLP-1 therapy—replacing the fragmented and often inconsistent experience many patients have faced with compounded alternatives. We look forward to expanding this collaboration to reach more patients and drive better outcomes at scale."

The partnership addresses growing demand from self-pay patients seeking FDA-approved replacements for compounded GLP-1 therapies. LifeMD's platform delivers an end-to-end care model spanning virtual consultation, prescription fulfillment, and ongoing coaching support, ensuring continuity throughout the weight loss journey.

Novo Nordisk's perspective on the collaboration emphasizes expanding access to authentic, FDA-approved therapy. "Novo Nordisk continues to work with LifeMD to expand access to authentic, FDA-approved Wegovy, a proven therapy for chronic weight management along with a reduced calorie diet and increased physical activity," said Dave Moore, Executive Vice President, US Operations of Novo Nordisk Inc. "This collaboration enables patients to begin their treatment journey through a trusted virtual care platform. We look forward to this collaboration and improving access and outcomes for patients nationwide."

LifeMD leverages its vertically integrated infrastructure, including a 50-state medical group and national diagnostic lab partnerships, to deliver personalized, clinically guided care across the United States. The company's weight management program addresses more than 200 conditions through its comprehensive virtual care platform.

Wegovy represents the first GLP-1 therapy approved in the United States for both chronic weight management and cardiovascular risk reduction in adults with obesity. The collaboration makes all Wegovy doses available in injector pen format to eligible LifeMD patients who are uninsured or whose insurance does not cover prescription weight-loss medications.

Click here for the original news story.